HomeBUSINESS
BUSINESS

EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
(Nov.7.2018)

Daiichi Sankyo said on November 6 that the European Medicines Agency (EMA) has accepted a marketing approval application (MAA) for quizartinib for the treatment of adults with relapsed or refractory FLT3-ITD positive acute myeloid leukemia (AML). The regulators also granted accelerated assessment status to the agent ...
(LOG IN FOR FULL STORY)